




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter

Evidence is Lacking for the NHS England Interim Guidance for Managing Metastatic Non-small Cell Lung Cancer in the COVID-19 Pandemic



Madam — Immunotherapy has improved non-small cell lung cancer (NSCLC) survival [1]. The COVID-19 pandemic has led NHS England to suggest stopping maintenance pemetrexed and using pembrolizumab monotherapy in patients with a tumour proportion score (TPS) < 50% [2].

Before immunotherapy, pemetrexed improved median overall survival (mOS) by 2.9 months [3,4]. In KEYNOTE-189, adding pembrolizumab improved mOS across all TPS subgroups [5]. However, the mOS in the TPS < 1% subgroup (17.2 months) was similar to pemetrexed maintenance studies. Given the higher rate of severe adverse events (71.9% versus 66.8%) and immune-related adverse events (10.9% versus 4.5%) with immunotherapy [5], pemetrexed monotherapy may be preferable in TPS < 1% patients.

KEYNOTE-042 randomised untreated metastatic NSCLC patients to pembrolizumab monotherapy or chemotherapy, showing a mOS of 20, 17.7 and 16.7 months in TPS groups >50%, >20%, >1%, respectively [6]. This was inferior to the mOS observed in KEYNOTE-189 (TPS 1–49%: 21.8 months; TPS < 1%: 17.2 months) [5]. KEYNOTE-407 assessed triple therapy in metastatic squamous NSCLC and showed a superior progression-free survival of 7.2 months (TPS 1–49% group) and 6.3 months (TPS < 1% group) [7] compared with the progression-free survival of 6.2 months (TPS > 20% group) and 5.4 months (TPS > 1% group) in KEYNOTE-042 [6]. Critically, in KEYNOTE-042, up to 72% of the lower TPS subgroups included patients with a TPS >50%, probably inflating the mOS observed [6].

The survival advantages of triple therapy come at a cost of higher rates of adverse events (71.9% versus 18%), particularly myelosuppression (15% versus <2%) [5,6]. Immune-related adverse events can be equally challenging to manage and may present with features that overlap with COVID-19 infection. Using immunosuppression was initially thought to be detrimental with COVID-19 [8], but the awaited RECOVERY trial publication may clarify this issue [9].

There is limited evidence for the efficacy of pembrolizumab monotherapy in TPS 0–49%. The European Medicines Agency has declined licensing for this indication

[10]. Despite interim guidance, there is an efficacy and safety trade-off that must be acknowledged.

Conflicts of interest

The authors declare no conflicts of interest.

M. Choudhury*, S. Nageshwaran†, D. Muthukumar*
* Colchester General Hospital, Colchester, UK

† Royal Marsden NHS Trust, London, UK

E-mail address: mahbubachoudhury38@yahoo.co.uk

References

- [1] Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, *et al.* Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? *Therapeut Adv Med Oncol* 2018;10. 1758835918762094.
- [2] NICE. Interim treatment change options during the COVID-19 pandemic endorsed by NHS England. Available at: <https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381>.
- [3] Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, *et al.* Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. *Lancet* 2009;374(9699):14321440.
- [4] Gridelli C, Maione P, Rossi A. The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. *Rev Recent Clin Trial*. 2013;8(1):23–28.
- [5] Gadgeel SM, Garassino MC, Esteban E, Speranza G, Felip E, Hochmair MJ, *et al.* KEYNOTE-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. *J Clin Oncol* 2019;37(15_suppl). 9013-9013.
- [6] Mok TS, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, *et al.* Pembrolizumab versus chemotherapy for previously

- untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2019;393(10183): 1819–1830.
- [7] Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, *et al.* Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *New Engl J Med* 2018;379(21): 2040–2051.
- [8] Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? *Ecancermedicalscience* 2020;14.
- [9] Wilkinson E. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials. *BMJ* 2020;369:m1626. <https://doi.org/10.1136/bmj.m1626>.
- [10] European Society of Medical Oncology. EMA does not recommend extending the use of pembrolizumab. Available at: <https://www.esmo.org/oncology-news/ema-does-not-recommend-extending-the-use-of-pembrolizumab>.